Research ArticleAsthma

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment

See allHide authors and affiliations

Science Translational Medicine  13 Feb 2019:
Vol. 11, Issue 479, eaao6451
DOI: 10.1126/scitranslmed.aao6451

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Smoothing out muscle in asthma

Asthma is often treated with drugs that reduce airway inflammation. Saunders et al. now show that fevipiprant, a prostaglandin D2 type 2 receptor antagonist, reduced smooth muscle mass in bronchial biopsies from asthma patients. Computational simulations of an asthmatic airway predicted that this decrease in airway smooth muscle mass was due to both amelioration of inflammation observed in a prior clinical trial together with direct effects on migration of myofibroblasts. Treating smooth muscle cells from bronchial biopsies from asthma patients with fevipiprant in vitro revealed that the drug-induced decrease in airway smooth muscle mass may be due to reduced migration of myofibroblasts and fibrocytes.

View Full Text